16 September 2026 editorial review · Item
Alefacept (CD2 memory T-cell targeting): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: T1DAL primary 12-month endpoint missed; secondary and 24-month C-peptide/hypoglycemia outcomes favorable. No current marketed T1D treatment established.
- Registry NCT00965458: TERMINATED; updated 2017-07-06; enrollment 49 (ACTUAL); primary completion 2013-03 (ACTUAL); results posted.
- Primary publication/regulatory sources checked or consulted: S2213-8587%2813%2970111-6; JCI81722.